Loading news...
Nephros (NASDAQ: NEPH - Get Free Report) and Envista (NYSE: NVST - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Volatility and Risk Nephros has a beta of 1.42, indicating
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
OPRX, NVST and STRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 16, 2026.
Envista (NVST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
EAT, PAHC and NVST made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 12th, 2026.
Envista (NVST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Clarkston Capital Partners LLC decreased its holdings in Envista Holdings Corporation (NYSE: NVST) by 8.2% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,317,255 shares of the company's stock after selling 386,075 shares during the quarter. Envista comprises approximately 1.9% of Clarkston
Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks offers value investors a better bang for their buck right now?
NVST shares jump 22% after Q4 EPS and revenue beat, with profits up 58% and double-digit segment growth despite gross margin pressure.
SANM, NVST and WDC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 12, 2026.
Broker upgrades make J, NVST and TPR top picks amid an AI-driven sell-off as markets demand clearer AI monetization and disciplined spending.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Envista (NVST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Envista (NVST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Envista (NVST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NVST, BBVA and PLXS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 9, 2026.